RavenQuest BioMed Inc. (RVVQF)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: May 8, 2025
RavenQuest BioMed Income Statement
Financials in millions CAD. Fiscal year is November - October.
Millions CAD. Fiscal year is Nov - Oct.
Fiscal Year | TTM | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | 2009 - 2013 |
|---|---|---|---|---|---|---|---|
Period Ending | Jul '19 Jul 31, 2019 | Oct '18 Oct 31, 2018 | Oct '17 Oct 31, 2017 | Oct '16 Oct 31, 2016 | Oct '15 Oct 31, 2015 | Oct '14 Oct 31, 2014 | 2009 - 2013 |
| Revenue | 1.52 | 1.26 | 0.11 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 0.80% | 1018.58% | - | - | - | - | Upgrade
|
| Cost of Revenue | 0.63 | 0.46 | 0.1 | - | - | - | Upgrade
|
| Gross Profit | 0.89 | 0.8 | 0.01 | - | - | - | Upgrade
|
| Selling, General & Admin | 5.41 | 4.97 | 0.56 | 0.07 | 0.07 | 0.08 | Upgrade
|
| Research & Development | 0.08 | 0.08 | - | - | - | - | Upgrade
|
| Operating Expenses | 14.68 | 13.44 | 0.61 | 0.07 | 0.07 | 0.08 | Upgrade
|
| Operating Income | -13.79 | -12.64 | -0.6 | -0.07 | -0.07 | -0.08 | Upgrade
|
| Interest Expense | -3.17 | -1.9 | -0.15 | - | - | - | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.87 | -4.89 | -0.05 | -0.01 | -0.01 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | -21.84 | -19.43 | -0.79 | -0.08 | -0.08 | -0.06 | Upgrade
|
| Merger & Restructuring Charges | - | - | -0.26 | - | - | - | Upgrade
|
| Impairment of Goodwill | -0.01 | -0.01 | -2.25 | - | - | - | Upgrade
|
| Asset Writedown | -11.71 | -11.71 | - | - | - | - | Upgrade
|
| Other Unusual Items | 0.63 | 0.11 | - | - | - | - | Upgrade
|
| Pretax Income | -32.93 | -31.05 | -3.3 | -0.08 | -0.08 | -0.06 | Upgrade
|
| Income Tax Expense | -0.58 | -0.58 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -32.35 | -30.47 | -3.3 | -0.08 | -0.08 | -0.06 | Upgrade
|
| Minority Interest in Earnings | - | - | 0 | - | - | - | Upgrade
|
| Net Income | -32.35 | -30.47 | -3.3 | -0.08 | -0.08 | -0.06 | Upgrade
|
| Net Income to Common | -32.35 | -30.47 | -3.3 | -0.08 | -0.08 | -0.06 | Upgrade
|
| Shares Outstanding (Basic) | 114 | 91 | 32 | 29 | 29 | 29 | Upgrade
|
| Shares Outstanding (Diluted) | 114 | 91 | 32 | 29 | 29 | 29 | Upgrade
|
| Shares Change (YoY) | 53.47% | 180.28% | 12.00% | - | - | - | Upgrade
|
| EPS (Basic) | -0.28 | -0.33 | -0.10 | -0.00 | -0.00 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.28 | -0.33 | -0.10 | -0.00 | -0.00 | -0.00 | Upgrade
|
| Free Cash Flow | -8.11 | -23.36 | -2.5 | -0.03 | -0.02 | -0.04 | Upgrade
|
| Free Cash Flow Per Share | -0.07 | -0.26 | -0.08 | -0.00 | -0.00 | -0.00 | Upgrade
|
| Gross Margin | 58.63% | 63.76% | 13.04% | - | - | - | Upgrade
|
| Operating Margin | -906.08% | -1005.86% | -530.18% | - | - | - | Upgrade
|
| Profit Margin | -2125.41% | -2424.36% | -2938.14% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -532.79% | -1858.93% | -2222.11% | - | - | - | Upgrade
|
| EBITDA | -9.9 | -10.76 | -0.6 | -0.07 | -0.07 | 0.32 | Upgrade
|
| D&A For EBITDA | 3.89 | 1.88 | 0 | 0 | 0 | 0.4 | Upgrade
|
| EBIT | -13.79 | -12.64 | -0.6 | -0.07 | -0.07 | -0.08 | Upgrade
|
| Advertising Expenses | - | 0.95 | - | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.